Drugs / emvistegrast
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06290934 | Mar 2024 → Mar 2026 overdue | ulcerative colitis | Gilead Sciences | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | emvistegrast | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06290934 ↗ |
| Route | Oral | “Administered orally” NCT06290934 ↗ |